Taliban: Biz IŞİD gibi düşünmüyor ve bakmıyoruz olaylara
f5haber.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from f5haber.com Daily Mail and Mail on Sunday newspapers.
Taliban: Mezhepçiliğe karşıyız
haksozhaber.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from haksozhaber.net Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced a strategic collaboration with Allegheny Health Network (AHN), a western Pennsylvania healthcare delivery system headquartered in Pittsburgh, PA. Under the agreement, Lantheus’ microbubbles will be used in combination with AHN’s ultrasound-assisted non-viral gene transfer (UAGT) technology for the development of a proposed treatment for xerostomia.
Xerostomia, a lack of saliva production leading to dry mouth, has a variety of causes, including radiotherapy and chemotherapy, the chronic use of drugs and rheumatic and dysmetabolic diseases.
Published: Mar 30, 2021
NORTH BILLERICA, Mass. (BUSINESS WIRE) Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced today it has acquired the exclusive, worldwide rights to develop, manufacture and commercialize NTI-1309, an innovative PET oncology imaging agent from Noria Therapeutics, Inc.
NTI-1309 targets fibroblast activation protein (FAP), a target with potential broad imaging applicability and targeting implications in oncology. FAP is overexpressed in the tumor microenvironment, specifically in tumor-associated fibroblasts, which are believed to modulate tumor progression and immune response. Given its expression in tumors coupled with low expression in normal tissue, FAP has the potential to become an important biomarker for precision medicine in cancer.